Article Text

Download PDFPDF

6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment
  1. E Serramontmany Morante1,
  2. I Cardona-Pascual1,
  3. P Garcia Ortega1,
  4. M Carreras Soler1,
  5. MQ Gorgas Torner1,
  6. I Cidoncha Muñoz1,
  7. E Felip Font2
  1. 1Vall d’Hebron University Hospital, Pharmacy Service, Barcelona, Spain
  2. 2Vall d’Hebron University Hospital, Oncology Service, Barcelona, Spain


Background and importance COVID-19 mortality changes depending on patients’ characteristics. The literature describes similar mortality in general COVID-19 patients and those receiving cancer therapies. However, cancer treatments represent a heterogeneous group.

Aim and objectives To evaluate how different cancer treatments can affect COVID-19 mortality in patients requiring hospital admission.

Material and methods Retrospective observational analysis conducted from March 2020 to February 2021 in a tertiary hospital.

Bio-demographic data (sex, age) and clinical data (type of cancer, ECOG, comorbidities) were obtained from the hospital records.

All adult oncological patients admitted for COVID-19, who had received anticancer drugs at least 6 weeks prior to hospital admission, were included.

Patients were classified according to type of treatment: chemotherapy, immunotherapy, hormonal therapies, or targeted-treatment.

Results Of 5633 cancer patients treated at our centre, 108 (1.9%) met the inclusion criteria and were included.

59 (54.6%) were men, median age 64 (21–96) years, 50 (46.3%) had ECOG 0 or 1.

Treatment received: chemotherapy (62, 57.4%), immunotherapy (32, 29.5%), targeted-therapy (23, 21.2%), hormone therapy (3, 2.7%) or another antineoplastic agent (6, 5.55%). The most frequent comorbidities were: hypertension (50, 46.3%), dyslipidaemia (33, 30.6%) and diabetes (24, 22.2%).

Half of the patients with lymphoid neoplasms (22, 20.3%) received chemotherapy (13; 59.1%) or immunotherapy (11; 50%).

Of 20 (18.5%) patients with gastrointestinal, 13 (12.0%) with lung and 12 (11.1%) with head and neck cancer, respectively, 14 (70%), 9 (69.2%) and 10 (83.3%) had received chemotherapy.

Mortality rate for all patients admitted to hospital with moderate-severe COVID was 10.4%, while patients included in our study had a higher mortality (n=38; 35.1%).

Higher mortality was associated with immunotherapy (40.6%) and targeted-therapy (43.4%). Chemotherapy was less related with mortality (28.5%). Anti-CD20 was the mechanism of action most related with mortality (n=10; mortality: 60%).

Conclusion and relevance Although some evidence suggests that recent exposure to systemic anticancer therapy does not increase COVID-19 mortality, our results show that in a subgroup of moderate-severe hospitalised patients, cancer treatment does increase COVID-19 mortality.

Immunotherapy and targeted-therapy could be more related to higher mortality rates than chemotherapy. Specifically, anti-CD20 have significantly higher mortality than other drugs.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.